相关实验视频
Updated: May 31, 2025
04:16
Electrocardiogram Recordings in Anesthetized Mice using Lead II
Published on: June 20, 2020
12.6K
评估莫梅洛替尼对心脏再极化的影响:彻底的QT研究
Georgios Vlasakakis1, Yolanda Alvarez2, Timothy Hart1
1GSK, Collegeville, PA, USA.
Clinical pharmacology in drug development
|January 23, 2025
概括
作为JAK抑制剂的Momelotinib在治疗剂量或超治疗剂量下,没有显著延长健康成年人的QT间隔 (QTc). 这项全面的QT研究没有发现与使用momelotinib的QTc延长相关的临床相关的心脏安全问题.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 心脏安全是药物开发的一个关键方面.
- 评估QT间隔延长的潜力是新药候选药物的监管要求.
- 莫梅洛提尼布是一种正在研究中的Janus激酶 (JAK) 抑制剂.
研究的目的:
- 为了评估momelotinib对健康成年人心率校正的QT间隔 (QTc) 的影响.
- 为了确定momelotinib,在治疗和超治疗剂量时,是否会导致临床上显著的QT延长.
- 评估momelotinib的药理动力学与QTcF变化之间的关系.
主要方法:
- 一个随机的,部分失明的,安慰剂控制的交叉研究.
- 48名健康成年人接受了momelotinib (200毫克和800毫克),moxifloxacin (400毫克,阳性对照) 和安慰剂.
- 电心电图 (ECG) 用弗里德里西亚公式分析了QTcF.
- 评估了momelotinib及其活性代谢物M21的药理动力学概况.
主要成果:
- 莫梅洛替尼没有延长QTcF;与安慰剂相比平均差异的90%置信区间的上限为<10毫秒.
- 通过莫西弗洛克萨显著延长QTcF证实了测试灵敏度.
- 在momelotinib血度和QTcF之间没有观察到积极的关系.
- 在超级治疗剂量时,不良反应更频繁,但不严重.
结论:
- 莫梅洛替尼在治疗剂量和超治疗剂量时,不会导致临床上显著的QT间隔延长.
- 这些发现支持了关于momelotinib对QT延长潜力的负面结论.
- 莫梅洛替尼在QTc间隔方面似乎具有良好的心脏安全概况.
更多相关视频
14:03High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
1.8K
08:03Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
Published on: October 20, 2022
1.7K
相关概念视频
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
895
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
895
01:30Cardiac Action Potential
915
Cardiac action potentials are essential for proper heart function, enabling the rhythmic contractions needed for adequate blood circulation. Nodal cells and Purkinje fibers, specialized for electrical conduction, generate these action potentials.
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
The cardiac action potential process involves a series of phases characterized by the movement of ions across the cardiac cell membranes, leading to the depolarization and repolarization of the cardiac myocytes.
Ionic Basis of Cardiac Action Potentials
915